Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies

Objective Studies in mouse models implicate complement activation as a causative factor in adverse pregnancy outcomes (APOs). We investigated whether activation of complement early in pregnancy predicts APOs in women with systemic lupus erythematosus (SLE) and/or antiphospholipid (aPL) antibodies. Methods The PROMISSE Study enrolled pregnant women with SLE and/or aPL antibodies (n=487) and pregnant healthy controls (n=204) at <12 weeks gestation and evaluated them monthly. APOs were: fetal/neonatal death, preterm delivery <36 weeks because of placental insufficiency or preeclampsia and/or growth restriction <5th percentile. Complement activation products were measured on serial blood samples obtained at each monthly visit. Results APO occurred in 20.5% of SLE and/or aPL pregnancies. As early as 12–15 weeks, levels of Bb and sC5b-9 were significantly higher in patients with APOs and remained elevated through 31 weeks compared with those with normal outcomes. Moreover, Bb and sC5b-9 were significantly higher in patients with SLE and/or aPL without APOs compared with healthy controls. In logistic regression analyses, Bb and sC5b-9 at 12–15 weeks remained significantly associated with APO (ORadj=1.41 per SD increase; 95% CI 1.06 to 1.89; P=0.019 and ORadj=1.37 per SD increase; 95% CI 1.05 to 1.80; P=0.022, respectively) after controlling for demographic and clinical risk factors for APOs in PROMISSE. When analyses were restricted to patients with aPL (n=161), associations between Bb at 12–15 weeks and APOs became stronger (ORadj=2.01 per SD increase; 95% CI 1.16 to 3.49; P=0.013). Conclusion In pregnant patients with SLE and/or aPL, increased Bb and sC5b-9 detectable early in pregnancy are strongly predictive of APOs and support activation of complement, particularly the alternative pathway, as a contributor to APOs.

[1]  R. Gibbs,et al.  The Relationship of Longitudinal Levels of Complement Bb During Pregnancy with Preeclampsia , 2016, American journal of reproductive immunology.

[2]  M. Belfort,et al.  Complement Split Products in Amniotic Fluid in Pregnancies Subsequently Developing Early-Onset Preeclampsia , 2015, Disease markers.

[3]  Mimi Y. Kim,et al.  Predictors of Pregnancy Outcomes in Patients With Lupus , 2015, Annals of Internal Medicine.

[4]  J. Salmon,et al.  Prevention of Defective Placentation and Pregnancy Loss by Blocking Innate Immune Pathways in a Syngeneic Model of Placental Insufficiency , 2015, The Journal of Immunology.

[5]  H. Baelde,et al.  Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia , 2015, Hypertension.

[6]  L. Chamley,et al.  Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature. , 2015, Autoimmunity reviews.

[7]  R. Fichorova,et al.  Urinary Excretion of C5b‐9 is Associated With the Anti‐Angiogenic State in Severe Preeclampsia , 2015, American journal of reproductive immunology.

[8]  R. Bellomo,et al.  Assessment of Cell-Cycle Arrest Biomarkers to Predict Early and Delayed Acute Kidney Injury , 2015, Disease markers.

[9]  M. Kolev,et al.  Complement — tapping into new sites and effector systems , 2014, Nature Reviews Immunology.

[10]  K. Kalunian,et al.  Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements , 2014, Lupus Science & Medicine.

[11]  V. Winn,et al.  Maternal and Fetal Alternative Complement Pathway Activation in Early Severe Preeclampsia , 2014, American journal of reproductive immunology.

[12]  R. Fichorova,et al.  Urinary Excretion of C5b-9 in Severe Preeclampsia: Tipping the Balance of Complement Activation in Pregnancy , 2013, Hypertension.

[13]  A. Tincani,et al.  Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? , 2012, Rheumatology.

[14]  F. Claas,et al.  Preeclampsia Is Characterized by Placental Complement Dysregulation , 2012, Hypertension.

[15]  S. Blackwell,et al.  Autoantibody-Mediated Complement C3a Receptor Activation Contributes to the Pathogenesis of Preeclampsia , 2012, Hypertension.

[16]  Mimi Y. Kim,et al.  Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. , 2012, Arthritis and rheumatism.

[17]  G. Sordo,et al.  Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome , 2012, Lupus.

[18]  P. Seed,et al.  Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome , 2012, Thrombosis and Haemostasis.

[19]  S. le Cessie,et al.  Classical complement activation as a footprint for murine and human antiphospholipid antibody‐induced fetal loss , 2011, The Journal of pathology.

[20]  J. Atkinson,et al.  Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort , 2011, PLoS medicine.

[21]  V. D’Agati,et al.  Targeted inhibition of complement activation prevents features of preeclampsia in mice. , 2011, Kidney international.

[22]  J. Salmon,et al.  Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. , 2010, Placenta.

[23]  V. Holers,et al.  The interrelationship of complement‐activation fragments and angiogenesis‐related factors in early pregnancy and their association with pre‐eclampsia , 2010, BJOG : an international journal of obstetrics and gynaecology.

[24]  T. Koike,et al.  Complement activation in patients with primary antiphospholipid syndrome , 2008, Annals of the rheumatic diseases.

[25]  J. Shamonki,et al.  Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. , 2007, American journal of obstetrics and gynecology.

[26]  J. Thurman,et al.  Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction , 2006, The Journal of experimental medicine.

[27]  J. Salmon,et al.  TNF-α Is a Critical Effector and a Target for Therapy in Antiphospholipid Antibody-Induced Pregnancy Loss1 , 2005, The Journal of Immunology.

[28]  J. Lambris,et al.  Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. , 2003, The Journal of clinical investigation.

[29]  Xiaowei Liu,et al.  Edinburgh Research Explorer Complement C3 activation is required for antiphospholipid antibody-induced fetal loss , 2022 .

[30]  B. Morgan,et al.  Immunology of reproduction: Protecting the placenta , 2000, Current Biology.

[31]  L. Sammaritano,et al.  Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. , 1997, Arthritis and rheumatism.

[32]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[33]  D. Cunningham,et al.  Decay-accelerating factor protects human trophoblast from complement-mediated attack. , 1995, Clinical immunology and immunopathology.

[34]  S. Meri,et al.  Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. , 1993, Journal of immunology.

[35]  S. Abramson,et al.  Activation of the Complement Pathway: Comparison of Normal Pregnancy, Preeclampsia, and Systemic Lupus Erythematosus During Pregnancy , 1992, American journal of reproductive immunology.

[36]  M. Tanner,et al.  Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. , 1990, Journal of immunology.

[37]  M. Wells,et al.  Complement component deposition in uteroplacental (spiral) arteries in normal human pregnancy. , 1987, Journal of reproductive immunology.

[38]  Mimi Y. Kim,et al.  Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. , 2016, American journal of obstetrics and gynecology.

[39]  J. Thurman,et al.  A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. , 2005, Molecular immunology.

[40]  S. Abramson,et al.  Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. , 1992, Arthritis and rheumatism.